---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-000244"
form_type: "8-K"
ticker: "URGN"
cik: "0001668243"
company_name: "UroGen Pharma Ltd."
filed_at: "2024-01-02T23:59:59+00:00"
generated_at: "2026-06-07T05:20:12.731140+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# UroGen amends manufacturing pact for UGN-102; extends term to 2027, commits €4.4M for equipment

## Summary
- Amendment to manufacturing agreement with Cenexi extends initial term to April 1, 2027.
- UroGen revised minimum annual quantity forecasts for bulk mitomycin purchases.
- Company agreed to reimburse up to €4.4 million for dedicated capital equipment for UGN-102 production.
- Amendment is in anticipation of potential approval and launch of UGN-102, a mitomycin product for low-grade upper tract urothelial cancer.
- Parties will negotiate final terms on equipment purchase, installation, and validation.

## SEC filing metadata
- accession: 0001193125-24-000244
- form_type: 8-K
- ticker: URGN
- cik: 0001668243
- company_name: UroGen Pharma Ltd.
- filed_at: 2024-01-02T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/0001193125-24-000244-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/d231255d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-000244
- JSON: https://secwatch.observer/filing/0001193125-24-000244.json
- Plain text: https://secwatch.observer/filing/0001193125-24-000244.txt

## Key facts
- Material Agreements
  UroGen Pharma Ltd. amended Amendment No. 2 to Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. valued at approximately €4.4 million (effective 2023-12-28).
  - Action: amendment
  - Agreement: supply
  - Counterparty: Cenexi-Laboratoires Thissen S.A.
  - Value: approximately €4.4 million
  - Effective: 2023-12-28
  source text: On December 28, 2023, UroGen Pharma Ltd. (the “Company”) entered into Amendment No. 2 (the “Amendment”) to its Manufacturing & Supply Agreement with Cenexi-Laboratoires Thissen S.A. (“Cenexi”), dated as of April 24, 2020 and amended as of March 2, 2022 (as amended by the Amendment, the “Agreement”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1668243/000119312524000244/0001193125-24-000244-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.